Fourth-quarter core EPS slightly below estimates

  • AstraZeneca expects double-digit growth in revenue and core earnings per share in 2024
  • Fourth-quarter core EPS slightly below estimates at $1.45
  • Total revenue for the quarter was $12.02 billion, slightly above expectations
  • Product sales rose to $11.32 billion

AstraZeneca reported fourth-quarter results with revenue in line with expectations and core earnings per share slightly below estimates. The company expects double-digit growth in revenue and core earnings per share in 2024, driven by the continued adoption of its medicines across geographies. Total revenue for the quarter was $12.02 billion, slightly above expectations, with product sales rising to $11.32 billion.

Public Companies: AstraZeneca (AZN)
Private Companies:
Key People: Pascal Soriot (Chief Executive)

Track all markets on TradingView

Factuality Level: 7
Justification: The article provides specific information about AstraZeneca’s revenue and core earnings per share for the fourth quarter and their expectations for growth in 2024. The information is based on the company’s reported results and statements from the Chief Executive. However, the article does not provide any independent analysis or perspectives from other sources, which could affect the overall factuality level.

Noise Level: 7
Justification: The article provides information on AstraZeneca’s revenue and earnings, but it lacks in-depth analysis or insights. It mainly focuses on the company’s financial performance and projections without exploring the underlying factors or potential risks. The article also lacks evidence or data to support its claims. Overall, it contains some relevant information but lacks depth and analysis.

Financial Relevance: Yes
Financial Markets Impacted: Pharmaceutical industry

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article pertains to the financial performance of AstraZeneca, a pharmaceutical company. It provides information on the company’s revenue and earnings growth projections for 2024. There is no mention of any extreme events or their impact.

Reported publicly: www.marketwatch.com